Why Abbott Labs Is Ready to Rebound
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health care giant Abbott Laboratories has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Abbott and see what CAPS investors are saying about the stock right now.
Abbott Park, Ill. (1888)
Chairman/CEO Miles White (since 1999)
Return on Equity (average, past 3 years)
Cash / Debt
$8.5 billion / $7.1 billion
Johnson & Johnson
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 2,606 members who have rated Abbott believe the stock will outperform the S&P 500 going forward.
Price/earnings good at 10.4, reasonable market cap, Return on Invested Capital (ROIC) [13.18%] last twelve trailing months, ROIC of over [10%] going back to 2007, Low debt/equity ratio of 0.15. Abbott Laboratories has 91,000 employees and strong value in both its generic drug segment and diagnostic segments.
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong five-star rating, Abbott may not be your top choice.
If you're looking for more long-term investing ideas, you're invited to check out The Motley Fool's brand-new special report, "The 3 Dow Stocks Dividend Investors Need." It's absolutely free, so simply click here now and get your copy today.
The article Why Abbott Labs Is Ready to Rebound originally appeared on Fool.com.Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.